This bill directs the National Institutes of Health and the U.S. Preventive Services Task Force to study hormone testing and hormone variability in women during perimenopause, the transition period before menopause. The NIH will evaluate existing published evidence about how hormone levels naturally vary in women before they experience perimenopause symptoms and identify any baseline patterns in this variability. The Preventive Services Task Force will review evidence about whether hormone testing is clinically useful and whether knowing a woman's baseline hormone levels before perimenopause symptoms appear helps with diagnosis and treatment. Within 18 months of the bill's enactment, both agencies must submit a joint report to Congress summarizing their findings, identifying gaps in the research, and recommending priorities for future research and clinical guidance. The bill does not specify dedicated funding amounts but tasks these existing agencies with conducting the research and reporting their results.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.